SCHEMBL9587796

SCHEMBL9587796

CCC(C([O])=O)c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.49
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
CNR2 P34972 2/20 0.41
MC4R P32245 3/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.39
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HIF1A Q16665 1/20 0.38
TSHR P16473 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966206 0.85 KCNQ2 (0.49) KCNQ2CES2CES1CNR2MC4R
SCHEMBL30427742 0.85 KCNQ2 (0.49) KCNQ2CES2CES1CNR2MC4R
SCHEMBL3364493 0.84 KCNQ2 (0.48) KCNQ2CES2CES1CNR2MC4R
SCHEMBL10779187 0.81 LMNA (0.51) KCNQ2CES2CES1CNR2MC4R
SCHEMBL17168998 0.81 KCNQ2 (0.46) KCNQ2CES2CES1CYP3A4GAA
SCHEMBL6722066 0.79 ESR1 (0.41) GAALMNAMEN1KMT2ATSHR
SCHEMBL27607833 0.79 CES2 (0.44) KCNQ2CES2CES1CNR2MC4R
SCHEMBL28080811 0.78 KCNQ2 (0.47) KCNQ2CES2CES1CNR2MC4R
SCHEMBL9588027 0.78 KCNQ2 (0.49) KCNQ2GAALMNAMEN1KMT2A
SCHEMBL27921084 0.77 CES2 (0.46) KCNQ2CES2CES1CNR2MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US claimed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP claimed
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US disclosed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP disclosed